| Literature DB >> 27859825 |
Heinrich C Weber1, Philip F Robinson2, Nicole Saxby3, Sean A Beggs4, Ingrid Els5, Rodney I Ehrlich6.
Abstract
INTRODUCTION: Although cystic fibrosis (CF) centre care is generally considered ideal, children living in regional Australia receive outreach care supported by the academic CF centres.Entities:
Keywords: comparative study; cystic fibrosis; cystic fibrosis centre; outreach care; paediatric
Mesh:
Year: 2016 PMID: 27859825 PMCID: PMC5347938 DOI: 10.1111/ajr.12334
Source DB: PubMed Journal: Aust J Rural Health ISSN: 1038-5282 Impact factor: 1.662
Levels of Paediatric CF care at CF clinics in Victoria and Tasmania
| Levels of CF Care | Predominant levels of outreach care | Details of delivery of CF care | Specific hospitals (Location) |
|---|---|---|---|
| CFC care |
At least 3 monthly review by MDT team | RCH (Melbourne) | |
| Outreach care | Shared care |
Regular care by local MDT |
LGH (Launceston) |
| Local care |
Majority of care provided by local CF MDT | RHH (Hobart) |
CFC, Cystic Fibrosis Centre; LGH, Launceston General Hospital; MDT, multidisciplinary team; NWRH, Northwest Regional Hospital; RCH, Royal Children's Hospital; RHH, Royal Hobart Hospital. MDT consists of: CF nurse, physiotherapist, dietician, psychologist, social worker, respiratory paediatrician (CFC) and general paediatrician (outreach care).
Underlying characteristics of children with CF being treated at three levels of care in Australia
| Cystic Fibrosis Centre | Shared | Local |
| |
|---|---|---|---|---|
| Number of patients | 272 | 49 | 29 | |
| Gender | ||||
| Males (%) | 142 (52.2%) | 30 (61.2%) | 16 (55.2%) | — |
| Female (%) | 130 (47.8%) | 19 (38.8%) | 13 (44.8%) |
|
| Age (years) [median (M), (IQR)] | 10.45 (5.2, 15.9) | 11.7 (5.0, 14.7) | 8.7 (4.0, 12.8) |
|
| Neonatal screening | 177 (65.1%) | 35 (71.4%) | 16 (55.2%) |
|
| Pancreatic insufficiency (%) | 225 (82.7%) | 45 (91.8%) | 26 (90.0%) |
|
| Genetics | ||||
| dF508/dF508 (%) | 115 (47.9%) | 19 (45.2%) | 7 (26.9%) | — |
| dF508/other (%) | 104 (43.3%) | 22 (52.4%) | 16 (61.5%) | — |
| other/other (%) | 21 (8.8%) | 1 (2.4%) | 3 (11.1%) |
|
| Missing | 32 | 7 | 3 | |
| SEIFA score for disadvantage (Binary) | ||||
| SES 1, 2 and 3 (most disadvantaged) | 138 (50.9%) | 37 (75.5%) | 18 (67.9%) | — |
| SES 4 and 5 | 133 (49.1%) | 12 (24.5%) | 9 (32.1%) |
|
| Missing SEIFA score | 1 | 0 | 1 | |
| ASGC categories | ||||
| 1 (Major city) | 133 (48.9%) | 12 (24.5%) | 1 (3.4%) | — |
| 2 (Inner regional) | 111 (40.8%) | 18 (36.7%) | 23 (79.3%) | — |
| 3 (Outer regional, remote and very remote) | 28 (10.3%) | 19 (38.8%) | 5 (17.2%) |
|
|
Nutrition: | 27.7 (18.0, 45.6) | 35.0 (16.9, 49.1) | 27.2 (15.0, 42.7) |
|
| Height (cm) | 130.0 (106.0, 157.0) | 142.2 (100.5, 157.2) | 129.2 (93.0, 152.7) |
|
| BMI (kg m−2) | 18.1 (16.1, 20.3) | 16.8 (15.2, 18.4) | 18.1 (17.7, 19.2) |
|
| Weight median z‐score | −0.02 (−0.68, 0.57) | −0.01 (−0.46, 0.38) | −0.06 (−0.26, 0.38) |
|
| Height median z‐score | −0.16 (−0.84, 0.43) | −0.35 (−0.79, 0.22) | −0.24 (−0.87, 0.28) |
|
| CF‐related diabetes mellitus | 18/265 (6.8%) | 1/46 (2.2%) | 3/29 (10.3%) |
|
| Management: | ||||
| Continuous oral antibiotic | 112/247 (49.4%) | 14/43 (32.6%) | 5/27 (18.5%) |
|
| Macrolide | 62 (22.8%) | 10 (20.4%) | 1 (3.4%) |
|
| DNAse | 78 (28.7%) | 21 (42.9%) | 17 (58.6%) |
|
| Airway colonisation | ||||
|
| ||||
| Negative | 171 (69.5%) | 29 (65.9%) | 9 (60.0%) | — |
| Single | 26 (10.6%) | 7 (15.9%) | 1 (6.7%) | — |
| ≥ 2 positive | 49 (19.9%) | 8 (18.2%) | 5 (33.3%) |
|
| MRSA | 5/246 (2.0%) | 2/44 (4.6%) | 0/15 (0%) |
|
|
| 6/248 (2.4%) | 2/44 (4.6%) | 0/15 (0%) |
|
Medians (M) and interquartile ranges (IQR) reported in brackets, unless otherwise stated. The P‐value is for any statistically significant difference between two of the groups. dF508, delta F508; SEIFA, Socio‐economic index for areas; BMI, body mass index; P. aeruginosa, Pseudomonas aeruginosa; MRSA, methicillin‐resistant Staphylococcus aureus; SES, socio‐economic status.
Clinical outcome in children with cystic fibrosis able to perform lung functions, by level of care
| Cystic Fibrosis Centre | Shared | Local |
| |
|---|---|---|---|---|
| Number | 163 | 31 | 19 | |
| Males (%) | 81 (49.7%) | 19 (61.3%) | 12 (63.2%) |
|
| Age [median years)] | 12.8 (9.5, 16.2) | 12.6 (9.5, 14.9) | 11.8 (8.7, 13.7) |
|
| Pancreatic insufficiency (%) | 134 (82.2%) | 28 (90.3%) | 17 (89.5%) |
|
| Anthropometry | ||||
| Height (cm) | 148.3 (129.0, 163.3) | 150.0 (130.0, 157.2) | 148.0 (129.2, 154.7) |
|
| Height z‐score | −0.14 (−0.84, 0.43) | −0.59 (−0.89, 0.12) | −0.24 (−0.76, 0.38) |
|
| BMI†(kg m−2) | 17.9 (15.9, 20.2) | 17.1 (15.9, 19.0) | 18.1 (17.6, 19.9) |
|
| BMI z‐scores | −0.12 (−0.74, 0.49) | −0.28 (−1.14, 0.42) | 0.12 (−0.24, 0.9) |
|
|
| ||||
| None | 68 (64.8%) | 15 (68.2%) | 5 (55.6%) | — |
| Present | 9 (8.6%) | 2 (9.1%) | 1 (11.1%) | — |
| Chronic | 28 (26.7%) | 5 (22.7%) | 3 (33.3%) |
|
| Lung function tests | ||||
| FEV1 (l) | 1.95 (1.4, 2.8) | 2.10(1.60, 2.70) | 1.80 (1.60, 2.40) |
|
| FEV1% predicted | 88.8%(75.8, 99.7) | 97.8 (80.6, 105.9) | 90.8% (77.6, 101.0) |
|
| Mean FEV1% | 83.2 (70.4, 94.3) | 87.3 (73.2, 101.1) | 83.8(66.5, 97.9) |
|
| FVC (litres) | 2.34 (1.73, 3.41) | 2.01(1.79, 3.55) | 2.33 (1.82, 2.99) |
|
| FEF25–75% | 1.7 (1.2, 2.7) | 2.0 (1.3, 2.8) | 1.9 (1.2, 2.6) |
|
Medians(M) and interquartile ranges (IQR) reported in brackets, unless otherwise stated. The P‐value is for any statistically significant difference in clinical outcome measures between the two of the groups of SES and Remoteness categories. BMI, body mass index; P aeruginosa, Pseudomonas aeruginosa; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; FEF25–75, forced expiratory flow rate 25% to 75% of FVC.
Comparing lung function (FEV1), body mass index (BMI) and P. aeruginosa colonisation across socio‐economic categories (SEIFA quintiles) and remoteness (ASGC classification) categories
|
| FEV1 (l) | BMI (kg m−2) | Ps Aer ≥2 | |
|---|---|---|---|---|
| Socio‐economic status – SEIFA (Disadvantage) categories | ||||
| Binary | ||||
| 1, 2 and 3 (Most disadvantaged) | 194 (55.8%) | 1.82 (1.41–2.62) | 17.7 (16.0–20.1) | 69 (35.6%) |
| 4 and 5 (Least disadvantaged) | 154 (44.2%) | 2.06 (1.48–2.76) | 18.3 (16.2–19.9) | 29 (24.0%) |
|
|
|
| ||
| Remoteness (ASGC categories) | ||||
| Major cities | 136 (41.1%) | 1.90 (1.38–2.65) | 17.34 (15.76–19.86) | 40 (30.2%) |
| Inner Regional | 144 (43.5%) | 2.04 (1.48–2.62) | 18.2 (16.36–19.91) | 46 (30.3%) |
| Outer regional – very remote | 51 (15.4%) | 1.96 (1.42–2.95) | 17.89 (15.56–20.42) | 17 (32.7%) |
|
|
|
| ||
Medians (M) and interquartile ranges (IQR) reported in brackets, unless otherwise stated. The P‐value is for any statistically significant difference in clinical outcome measures between the two of the groups of SES and Remoteness categories. ASGC, Australian Standard for Geographical Classification; BMI, body mass index; FEV1, forced expiratory volume in 1 s; Ps Aer≥2, two or more positive cultures of Pseudomonas aeruginosa; SEIFA, Socio‐economic index for area (disadvantage); SES, Socio‐economic status.
Lung function in children with cystic fibrosis able to perform lung functions, by level of care, stratified by SES
| Lung function parameters | Cystic Fibrosis Centre | Shared care | Local care |
|
|---|---|---|---|---|
| FEV1 (l) | ||||
| SES 1–3 | 1.8 (1.39, 2.64) | 2.1 (1.52, 2.57) | 1.7 (1.54, 2.25) | — |
| SES 4–5 | 2.1 (1.41, 2.76) | 2.0 (1.87–3.1) | 2.1 (1.61, 2.5) |
|
| FEV1% predicted (%) | ||||
| SES 1–3 | 90.7 (76.1, 102.9) | 89.3 (80.6, 103.9) | 85.0 (67.44, 94.54) | — |
| SES 4–5 | 87.5 (75.7, 96.3) | 102.6 (92.2, 117.6) | 99.3 (85.32, 106.31) |
|
| FVC (l) | ||||
| SES 1–3 | 2.2 (1.73, 3.27) | 2.6 (1.79, 3.01) | 2.3 (1.85, 3.04) | — |
| SES 4–5 | 2.5 (1.78, 3.44) | 2.5 (2.16, 3.55) | 2.6 (1.82, 2.99) |
|
| FEF 25–75 (l/s) | ||||
| SES 1–3 | 1.7 (1.27, 2.7) | 1.8 (1.22, 2.76) | 1.7 (1.13, 2.06) | — |
| SES 4–5 | 1.7 (1.13, 2.74) | 2.4 (1.65, 3.34) | 2.6 (2.19, 2.64) |
|
| FEV1/FVC <80% | ||||
| SES 1–3 | 27/81 (33.3%) | 9/25 (36.0%) | 8/19 (42.1%) | — |
| SES 4–5 | 37/82 (45.1%) | 1/6 (16.7%) | 0/9 (0%) |
|
Medians (M) and interquartile ranges (IQR) reported in brackets, unless otherwise stated. The P‐value is for any statistically significant difference in lung function outcome measures between two of the SES groups. FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; FEF25–75, forced expiratory flow rate 25% to 75% (mid‐expiratory flow rate); SES, Socio‐economic status; SEIFA (Disadvantage), Socio‐economic index for area classification for disadvantage.